BioNTech Lung Cancer Drug Extends Survival Versus Chemotherapy
BioNTech SE said its experimental drug gotistobart nearly doubled the median survival of patients with an aggressive form of lung cancer compared to chemotherapy.
By Sonja Wind · Bloomberg
BioNTech SE said its experimental drug gotistobart nearly doubled the median survival of patients with an aggressive form of lung cancer compared to chemotherapy.